Compare TG Therapeutics Inc (TGTX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs 22nd Century Group Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while 22nd Century Group Inc trades at $2.17 (market cap $1.62M). The key difference: TG Therapeutics Inc is far larger — about 5265.4× 22nd Century Group Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | XXII | |
|---|---|---|
Market Cap | $8.53B | $1.62M |
Sector | Health | Technology |
52-Week High | $59.06 | $594.00 |
52-Week Low | $26.94 | $2.13 |
Enterprise Value | $8.74B | -$2.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
